SLC5A2 and hydrops fetalis: Furthermore, although the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors has been demonstrated for HF across all LVEF categories,11,12 these cohorts include patients with various underlying heart diseases and still have residual heterogeneity.